Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta, Tel Aviv University to Collaborate on microRNA Drug Delivery Tech

Premium

Rosetta Genomics said this week that it has entered a sponsored research arrangement with Tel Aviv University tech-transfer subsidiary Ramot to develop a delivery technology for microRNA mimic-based cancer therapies.

The deal calls for the partners to work together for one year and jointly own data and intellectual property resulting from the alliance. Rosetta will contribute around $69,000 to fund research at Ramot.

Although Rosetta was founded to develop both miRNA diagnostics and therapeutics, the company has largely focused on its diagnostics efforts. However, it has been working with Ramot for several years on miRNA mimics, including one based on miR-34a for cancer (GSN 8/8/2013).

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.